Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Assisted Psychotherapy for Severe Irritable Bowel Syndrome
NCT06760533Phase 1Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial in irritable bowel syndrome (IBS) comparing Intervention: Psilocybin with Control: Niacin (Placebo) (2 arms). Primary endpoint: Abdominal Pain Severity Numeric Rating Scale at Week 6. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06760533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760533.